| Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up. | |
| | |
MedLine Citation:
|
PMID: 17877729 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In 1995, AAFACT, a new monoclonal purified factor VIII concentrate (FVIII), derived from human plasma, was introduced in the Netherlands. The monoclonal purification based production process includes a viral inactivation step by solvent/detergent treatment. Products manufactured according to this procedure, for example Hemofil M are used worldwide. The aim of the present study was to assess inhibitor development in a large cohort of previously treated patients (PTPs) who were followed up for 10 years. In addition, efficacy, HIV and hepatitis C virus (HCV) transmission, and allergic reactions were monitored. All 165 patients with severe haemophilia A (FVIII<1%) known at the van Creveldkliniek who ever used AAFACT during the period from October 1995 to September 2005 were included. Two of them were previously untreated patients (PUPs) and two others had <50 exposure days. Data on FVIII consumption, number of exposures, bleedings and hospitalization days were collected from start of AAFACT until last clinical and laboratory evaluation while on this product. At the end of follow-up, 91 patients were still using this plasma-derived FVIII. Median age at start of follow-up was 26 years (range 1-52). None of the patients reported lack of efficacy. Median FVIII consumption per patient during follow-up was 2058 IU kg(-1) bodyweight per year, and median number of exposures was 148 per year. During 1029 patient-years of follow-up, one inhibitor was diagnosed in a previously treated patient PTP. This patient developed high titre inhibitor following surgery for which he, during 1 week, had been treated with continuous infusion with recombinant FVIII. No inhibitor occurred during 68 cases of surgery using continuous infusion with AAFACT. No viral transmissions or other adverse events occurred during 10 years of follow-up; AAFACT appeared to be an effective and safe FVIII product. |
| | |
Authors:
|
E P Mauser-Bunschoten; D Posthouwer; K Fischer; H M van den Berg |
Related Documents
:
|
9134639 - A multicenter study of recombinant factor viii (recombinate) in previously treated pati... 11037719 - Floseal: a new hemostyptic agent in peripheral vascular surgery. 1462009 - Performance characteristics of contemporary hemodialysis and venovenous hemofiltration ... 9771409 - Transcatheter coil embolotherapy: a safe and effective option for major colonic haemorr... 2308359 - A new technique for one-stage radical eradication of long-standing chronic thoracic emp... 1858759 - Same-day upper and lower inpatient endoscopy: a trend for the future. 18936119 - Proximal row carpectomy with or without postoperative immobilisation. 8639069 - A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in t... 18363059 - Influence of thoracic epidural analgesia on postoperative pain relief and ileus after l... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2007-09-18 |
Journal Detail:
|
Title: Haemophilia : the official journal of the World Federation of Hemophilia Volume: 13 ISSN: 1351-8216 ISO Abbreviation: Haemophilia Publication Date: 2007 Nov |
Date Detail:
|
Created Date: 2007-11-01 Completed Date: 2008-04-11 Revised Date: 2009-10-21 |
Medline Journal Info:
|
Nlm Unique ID: 9442916 Medline TA: Haemophilia Country: England |
Other Details:
|
Languages: eng Pagination: 697-700 Citation Subset: IM |
Affiliation:
|
Van Creveldkliniek, Division of Internal Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands. E.Mauserbunschoten@umcutrecht.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Child Child, Preschool Cohort Studies Factor VIII / standards, therapeutic use* Female Follow-Up Studies Hemophilia A / drug therapy* Humans Infant Male Middle Aged Orthopedic Procedures / methods, rehabilitation*, statistics & numerical data Product Surveillance, Postmarketing Virus Diseases / prevention & control, transmission |
| Chemical | |
Reg. No./Substance:
|
9001-27-8/Factor VIII |
| Comments/Corrections | |
Comment In:
|
Haemophilia. 2008 May;14(3):612-4
[PMID:
18312362
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fate of the sblA transcript in Streptomyces lividans and Escherichia coli.
Next Document: Association patterns of Pseudomonas aeruginosa clinical isolates as revealed by virulence traits, an...